ImageneBio Inc
NASDAQ:IMABiotechnology
+$0.35 today
- Market cap
- $52.00M
- Beta
- 0.72
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.02
Volume 0.00M
Average 0.35M
IMA Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
ImageneBio IncNASDAQ: IMA
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow turns negative
Q1 FY2026 investing cash flow was -$440K, compared with $7.93M a year earlier. Trailing-twelve-month investing cash flow was -$14.19M. Over 3 fiscal years it compounded at -61.2% a year.
Context
- Investing cash flow amounted to 726.8% of revenue in FY2025, down 270.5 pp from a year earlier.
- Investing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly investing cash flow holds near -$440K or moves back toward the trailing-twelve-month quarterly average of -$3.55M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (5.81M) USD
- Year-over-year change
- +83.3%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.81M) | +83.3% |
| FY2024 | 2024-12-31 | (34.9M) | -154.4% |
| FY2023 | 2023-12-31 | 64.14M | +164.6% |
| FY2022 | 2022-12-31 | (99.28M) | -5541.1% |
| FY2021 | 2021-12-31 | (1.76M) | — |
Investing Cash Flow vs competitors
How IMA compares with its peers on the latest reported figures
- Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -165.2% is the 7th highest of 8, against a peer median of -88.4%.
- Over three fiscal years its annual growth of -61.2% compares with a peer median of -17.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $70.07M USD | — | — | — |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $68.76M USD | +157.2% | — | — |
| LTM Mar 2026 | $49.01M USD | -224.0% | -17.2% | 688.1% | |
| LTM Mar 2026 | $16.01M USD | -88.4% | — | 16.1% | |
IMAImageneBio Inc | LTM Mar 2026 | $14.19M USD | -165.2% | -61.2% | — |
| FY2025 | $9.82M USD | +384.5% | — | 15340.6% | |
| LTM Mar 2026 | €8.18M EUR | -119.0% | -45.7% | 27899.4% | |
| LTM Mar 2026 | $2.04M USD | -86.2% | +55.9% | — | |
| LTM Mar 2026 | $361K USD | -99.1% | — | 36.1% | |
| Peer median (excluding IMA) | — | -88.4% | -17.2% | 688.1% | |
Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (34.12M) | (68.77M) | (68.17M) | (49.23M) | (52.4M) |
| Depreciation & Amortization | 544K | 751K | 1.02M | 490K | 328K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.18M | 7.53M | 0 | 5.3M | 15.39M |
| Change in Working Capital | (33.03M) | (15.14M) | (21.67M) | (3.98M) | (19.19M) |
| Accounts Receivables | 361K | (291K) | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | (2.87M) | (1.17M) | (2.82M) |
| Other Working Capital | (33.39M) | (14.85M) | (18.8M) | (2.81M) | (16.37M) |
| Other Non-Cash Items | 1.17M | 1.52M | 9.07M | 1.42M | 8.02M |
| Operating Cash Flow | (60.25M) | (74.11M) | (79.74M) | (46M) | (47.84M) |
| Capital Expenditures | (1.76M) | (1.43M) | (414K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (5.22M) |
| Purchases of Investments | 0 | (216.34M) | (90.05M) | (88.3M) | (10.4M) |
| Sales of Investments | 0 | 118.49M | 154.61M | 60.46M | 9.8M |
| Other Investing Activities | 0 | 0 | 0 | (7.07M) | 0 |
| Investing Cash Flow | (1.76M) | (99.28M) | 64.14M | (34.9M) | (5.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 15M |
| Common Stock Issued | 131.3M | 0 | 37.56M | 0 | 65.84M |
| Common Stock Repurchased | 0 | 0 | (663K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 582K | 1.1M | 39.09M | 0 | 54.63M |
| Financing Cash Flow | 131.74M | 1.1M | 75.98M | 0 | 135.47M |
| Effect of Forex Changes | 0 | 0 | (406K) | 0 | 604K |
| Net Change in Cash | 69.73M | (172.3M) | 59.98M | (80.91M) | 82.41M |
| Free Cash Flow | (62.01M) | (75.54M) | (80.16M) | (46M) | (47.84M) |
ImageneBio Inc
NASDAQ:IMA
Intrinsic Alpha fair value
Locked
Current Price
$4.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.